Please login to the form below

Not currently logged in

Pfizer expands its generics portfolio

Pfizer has entered into licensing agreements with two pharmaceutical companies in India, strengthening its position in emerging markets

Pfizer has entered into licensing agreements with two pharmaceutical companies in India, strengthening its position in emerging markets and significantly expanding its Established Products Business Unit's medicines portfolio.

Under the terms of the expanded agreements with Aurobindo Pharma, Pfizer has acquired rights to 55 solid oral dose products and 5 sterile injectable products for patients in more than 70 emerging market countries. These medicines include antibiotics and anti-infectives and cover a broad range of disease areas such as cardiovascular and central nervous system disorders. Pfizer plans to commercialise the 60 products in phases, tailoring its approach for different regions. Financial terms of the deal have not been disclosed.

"This deal illustrates the types of innovative partnerships which will help to advance Pfizer's presence in developing markets and enhance access to needed medicines for billions worldwide," said Jean-Michel Halfon, president and general manager of Pfizer's Emerging Markets Business Unit. "The expansion of our product portfolio from this deal provides a foundation for us to commercialise branded generics based on patient needs within specific regions."

Pfizer also entered into agreements with Claris Lifesciences to commercialise sterile injectable medicines after the products are no longer patent protected and have lost market exclusivity in North America, Europe, Australia and New Zealand. The Claris agreements advance Pfizer's Established Products strategy, which focuses on the commercialisation of products where market exclusivity has been lost. Pfizer's global annual sales of established products are approximately $10bn.

Through these agreements, Pfizer acquires rights to 15 injectable products covering a broad range of therapeutic areas including anti-infectives and pain. Financial terms of this deal were not disclosed either.

"These agreements advance our goals to expand our steriles portfolio and provide hospitals and patients with a wide offering of affordable medicines they can trust. Pfizer's reputation for high quality and supply reliability is unrivaled in the industry, and this is critical in the area of sterile injectables," said David Simmons, president and general manager of Pfizer's Established Products Business Unit.

Pfizer also expanded agreements with Aurobindo in developed markets, adding products in the US and Europe.

To date, 128 non-Pfizer products - 98 solid oral dose and 30 sterile injectables – have been added to the Company's existing diversified portfolio of established brands.

"Today's announcement demonstrates Pfizer's commitment to improving the global public health landscape by making needed quality medicines - in a range of disease areas - accessible to underserved populations worldwide," said Jeff Kindler, chairman and CEO of Pfizer. "The off-patent marketplace worldwide too often suffers from quality and supply reliability issues. With our broad established medicines portfolio and our world-class manufacturing capabilities, Pfizer is in an ideal position to supply high-quality medicines at affordable prices to people around the world."

21st May 2009


Featured jobs

Subscribe to our email news alerts


Add my company

Latest intelligence

If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked